Skip to main content
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;23(Suppl 3):III6–III10. doi: 10.1002/clc.4960231503

The economic burden of heart failure

J B O'Connell 1,
PMCID: PMC6654942  PMID: 10754775

Abstract

Heart failure, a major cause of morbidity and mortality among the elderly, is a serious public health problem. As the population ages and the prevalence of heart failure increases, expenditures related to the care of these patients will climb dramatically. As a result, the health care industry must develop strategies to contain this staggering economic burden. Strategies may include adopting approaches for preventing heart failure and implementing new treatment modalities with proven efficacy into large‐scale clinical practice. Successful implementation of these strategies will require intensive physician and patient education and development of innovative approaches to fund support services.

Keywords: heart failure, economic burden, aging population, angiotensin‐converting enzyme inhibitors, beta blockers, hospitalization costs

Full Text

The Full Text of this article is available as a PDF (502.3 KB).

References

  • 1. Kannel WB, Ho K, Thom T: Changing epidemiological features of cardiac failure. Br Heart J 1994; 72: S3–S9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Anonymous : Mortality from congestive heart failure—United States, 1980–1990. Morbidity and Mortality Weekly Report 1994; 43: 77–81 [PubMed] [Google Scholar]
  • 3. Bodenheimer T: The American health care system—the movement for improved quality in health care. N Engl J Med 1999; 340: 488–492 [DOI] [PubMed] [Google Scholar]
  • 4. O'Connell JB, Bristow MR: Economic impact of heart failure in the United States: Time for a different approach. J Heart Lung Transplant 1994; 13: S107–S112 [PubMed] [Google Scholar]
  • 5. American Heart Association : 1999 Heart and Stroke Statistical Update, Dallas, Tex: American Heart Association, 1998. [Google Scholar]
  • 6. Rich MW: Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997; 45: 968–974 [DOI] [PubMed] [Google Scholar]
  • 7. Croft JB, Giles WH, Pollard RA, Keenan NL, Casper ML, Anda RF: Heart failure survival among older adults in the United States: A poor prognosis for an emerging epidemic in the Medicare population. Arch Intern Med 1999; 159: 505–510 [DOI] [PubMed] [Google Scholar]
  • 8. Rich MW: Heart failure. Cardiol Clin 1999; 17: 123–135 [DOI] [PubMed] [Google Scholar]
  • 9. McKinnon ME, McKee CM: Heart failure: The Cinderella of cardiology? Public Health 1996; 110: 351–355 [DOI] [PubMed] [Google Scholar]
  • 10. Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T: Early readmission of elderly patients with congestive heart failure. J Amer Geriatric Soc 1990; 38: 1290–1295 [DOI] [PubMed] [Google Scholar]
  • 11. Ely JW, Burch RJ, Vinson DC: The information needs of family physicians: Case‐specific clinical questions. J Fam Pract 1992; 35: 265–269 [PubMed] [Google Scholar]
  • 12. United Network for Organ Sharing. U.S. Facts about Transplantation. 1998. Richmond, Va, United Network for Organ Sharing; [Google Scholar]
  • 13. Massie BM, Shah NB: Evolving trends in the epidemiologic factors of heart failure: Rationale for preventive strategies and comprehensive disease management. Am Heart J 1997; 133: 703–712 [DOI] [PubMed] [Google Scholar]
  • 14. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293–302 [DOI] [PubMed] [Google Scholar]
  • 15. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes CV, Carson P, Cintron G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine‐isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–310 [DOI] [PubMed] [Google Scholar]
  • 16. The CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987; 316: 1429–1435 [DOI] [PubMed] [Google Scholar]
  • 17. Miller LW, Merkle EJ, Jennsion SH: Outpatient use of dobutamine to support patients awaiting heart transplantation. Transplantation 1994; 13: S126–S129 [PubMed] [Google Scholar]
  • 18. Ho KKL, Anderson KM, Kannel WB, Grossman W, Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88: 107–115 [DOI] [PubMed] [Google Scholar]
  • 19. McDermott MM, Feinglass J, Lee P, Mehta S, Schmitt B, Lefevre F, Puppala J, Gheorghiade M: Heart failure between 1986 and 1994: Temporal trends in drug‐prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J 1997; 134: 901–909 [DOI] [PubMed] [Google Scholar]
  • 20. The Large State Peer Review Organization Consortium : Heart failure treatment with angiotensin‐converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. The Large State Peer Review Organization Consortium. Arch Intern Med 1997; 157: 1103–1108 [PubMed] [Google Scholar]
  • 21. Stafford RS, Saglam D, Blumenthal D: National patterns of angiotensin‐converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997; 157: 2460–2464 [PubMed] [Google Scholar]
  • 22. Rajfer SI: Perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol 1993; 22: 198A–200A [DOI] [PubMed] [Google Scholar]
  • 23. Ghali JK, Giles T, Gonzales M, Horswell R, Kumar S, Lejuene A, Livaudais GF, Sarkar IC: Patterns of physician use of angiotensin converting enzyme inhibitors in the inpatient treatment of congestive heart failure. J La State Med Soc 1997; 149: 474–484 [PubMed] [Google Scholar]
  • 24. Packer M: Do angiotensin‐converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? (editorial). J Am Coll Cardiol 1996; 28: 1323–1327 [DOI] [PubMed] [Google Scholar]
  • 25. Hobbs RE: Results of the ATLAS study. High or low doses of ACE inhibitors for heart failure? Cleve Clin J Med 1998; 65: 539–542 [DOI] [PubMed] [Google Scholar]
  • 26. Sueta CA, Chowdhury M, Boccuzzi SJ, Smith SC Jr, Alexander CM, Londhe A, Lulla A, Simpson RJ Jr: Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 1999; 83: 1303–1307 [DOI] [PubMed] [Google Scholar]
  • 27. American College of Cardiology/American Heart Association Task Force on Practice Guidelines : Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). J Am Coll Cardiol 1995; 26: 1376–1398 [PubMed] [Google Scholar]
  • 28. DiMatteo MR, Sherbourne CD, Hays RD, Ordway L, Kravitz RL, McGlynn EA, Kaplan S, Rogers WH: Physicians' characteristics influence patients' adherence to medical treatment: Results from the Medical Outcomes Study. Health Psychol 1993; 12: 93–102 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES